Bli medlem
Bli medlem

Du är här


ContextVision AB : ContextVision/HES-SO Team among Top Three in Prestigious Competition using Deep Learning in Digital Pathology

STOCKHOLM - Oct. 18, 2016
- ContextVision, a medical technology company specializing in image analysis and artificial intelligence, placed top three among automated image analysis in the Tumor Proliferation Assessment Challenge (TUPAC) 2016 competition with its SLDESUTO partner (HES-SO). Many prestigious teams participated, including both highly reputable academic teams and research groups from companies like IBM and Microsoft. Participating teams were given a dataset of whole slide images, and one of the tasks was to assess tumor proliferation speed by applying machine learning algorithms. "We achieved good results by applying deep learning, which is a hot technology within artificial intelligence," said Anita Tollstadius, ContextVision CEO. "While many companies are in the process of learning the technology, ContextVision has invested in moving to the forefront of knowledge in deep learning and artificial intelligence. This result proves that we have developed our skills to reach an international top level. We really are on track for developing our platform within digital pathology", said Tollstadius. The tumor proliferation speed (tumor growth) is an important biomarker indicative of breast cancer patients' prognosis. Breast cancer patients with high tumor proliferation speed have worse outcomes compared to patients with low tumor proliferation speed. Thus, the assessment of this biomarker influences the decisions for the treatment plan of the patient. "The participation in this challenge on digital pathology images from breast cancer marks a broadening of our present scope for the SLDESUTO project within digital pathology," Tollstadius said. The competition was organized by the 19thInternational Conference on Medical Image Computing&Computer Assisted Intervention (MICCAI) at the InterContinental Athenaeum Hotel in Athens.
For further information, please contact ContextVision's CEO, Anita
Tollstadius, at +46 70 337 30 26.


The SLDESUTO project received funding from the Eurostars-2 Joint Program with
co-funding from the European Union's Horizon 2020 research and innovation
program. This is a joint project between ContextVision AB, in Linköping,
Sweden and the eHealth unit of HES-SO, University of Applied Sciences Western
Switzerland in Sierre, Switzerland. State-of-the-art machine learning
algorithms including deep learning will be used to train the software to
automatically recognize, identify and classify abnormal patterns in digital
images with a variety of pathologies. The purpose of this project is to use
unique technology and knowledge to develop a Decision Support Toolbox (DST),
that will support the pathologists in their challenging task to diagnose and
evaluate the prognosis of different types of cancer.

About ContextVision

ContextVision is a medical technology company specializing in image analysis
and image processing. Its cutting-edge technology helps doctors more
accurately interpret medical images, a crucial foundation for better
diagnosis and treatment. As an industry pioneer for more than 30 years,
ContextVision has decided to take a lead position within deep learning, the
latest technology within artificial intelligence. ContextVision is currently
investing heavily in this field to develop a broader product portfolio. The
present product portfolio includes state-of-the-art image enhancement
software for 2D/3D/4D ultrasound, MRI, X-ray and mammography and is used by
leading equipment manufacturers worldwide. ContextVision is based in Sweden
and listed on the Oslo Stock Exchange under the ticker COV. For more
information, please

Press release October 18 2016


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ContextVision AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.